Alzheimer's disease (AD) is a major healthcare challenge with no curative treatment at
present. To address this challenge, we need a paradigm shift, where we focus on pre …

Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …

Staging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration
could identify individuals at risk for cognitive decline in Alzheimer's disease (AD). In blood …

Mass spectrometry-based proteomics empowers deep profiling of proteome and protein
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …

Data-driven disease progression models are an emerging set of computational tools that
reconstruct disease timelines for long-term chronic diseases, providing unique insights into …

The risk-benefit profile of anti-Aβ monoclonal antibodies (mAbs) in Alzheimer's disease (AD)
remains unclear, especially concerning their safety and overall effects on AD progression …

Understanding Alzheimer's disease (AD) heterogeneity is important for understanding the
underlying pathophysiological mechanisms of AD. However, AD atrophy subtypes may …

Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) has
accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic …

Abstract Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid
(CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly …